Cell MedX announced its Canadian subsidiary signed a production agreement with a manufacturing facility in British Columbia.
Cell MedX (OTCQB:CMXC) announced its Canadian subsidiary signed a production agreement, effectively moving manufacturing duties to a facility in British Columbia.
As quoted in the press release:
The move is intended to allow the Company to facilitate its planned distribution under the current registration with the U.S. Food and Drug Administration while ensuring lower production costs and greater control of the manufacturing and distribution process. Furthermore, it will assist the Company with setting up its standard operating procedures under ISO 13485-2016, a requirement by Health Canada to register the Company’s eBalance Pro device as Class II medical device.
Mr. McEnulty, the Company’s CEO, stated: “Our team is very excited to continue moving ahead with our strategic plan. The new relationships that we secured with both the manufacturing facility as well as with our new suppliers is the next essential step to bring our eBalance Pro device to market.”